Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Clinical trial NCT03650894 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03650894
Sponsor: Providence Health & Services
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Neoplasm Female Breast Cancer Breast Carcinoma Breast Tumor

Start date: 2019-04-03
Primary completion: 2023-03-10
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.